Development asset linked to Recordati Ireland in public FDA and regional records.
pharma · Post-bariatric hypoglycaemia · Cushing's disease
Recordati Ireland
Recordati Ireland drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cork, IE HQ
2002 Founded
40 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cork, IE
- Founded
- 2002
- Employees
- 40
- Programs
- 4
- Drugs
- 11
- Patents
- 0
Recordati Ireland pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Recordati Ireland drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Recordati Ireland in public FDA and regional records.
-
Development asset linked to Recordati Ireland in public FDA and regional records.
-
osilodrostat
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in Recordati Ireland's portfolio. Mechanism: Cytochrome P450 11B1 inhibitor.
- Mechanism
- Cytochrome P450 11B1 inhibitor
-
US regulatory status: approved. Molecular target: Cytochrome P450 11B1, mitochondrial.
- Target
- Cytochrome P450 11B1, mitochondrial
- Mechanism
- Cytochrome P450 11B1 inhibitor
-
pasireotide
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Recordati Ireland's portfolio. Mechanism: Somatostatin receptor 1 agonist.
- Mechanism
- Somatostatin receptor 1 agonist
-
Development asset linked to Recordati Ireland in public FDA and regional records.
-
Development asset linked to Recordati Ireland in public FDA and regional records.
-
Development asset linked to Recordati Ireland in public FDA and regional records.
-
Development asset linked to Recordati Ireland in public FDA and regional records.